Katie King, Co-founder & CEO, BioOrbit | Slush 2025
summary
BioOrbit claims it will mass-produce pharmaceutical-grade antibody crystals in microgravity to turn IV cancer immunotherapies into high-concentration auto-injectors, eliminate cold chains, and enable controlled release. Hardware roadmap centers on Baby Boxy for next-summer validation and two platforms, Box S and Box R (re-entry capsule and station-deployed), with the next launch already the largest space crystallization run, two launches within 24 months, £2M+ raised, GMP target 2028 and a 2027 proof-of-concept injectable.
AI-written summary · about